Study guide
18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge
Key Takeaways Explain This Topic AI
Healthy People 2030 groups social determinants of health into five domains: economic stability, education access and quality, health care access and quality, neighborhood and built environment, and social and community context.
The Joint Commission's 2026 National Performance Goals require hospitals to assess patients' health-related social needs, such as transportation, food, housing and difficulty paying for prescriptions.
CMS removed its two hospital SDOH screening measures from the Inpatient Quality Reporting program in the FY 2026 IPPS final rule, but accreditation and clinical reasons to screen remain.
The Medicare Part D annual out-of-pocket cap is $2,100 in 2026, and Medicare limits covered insulin cost sharing to $35 a month.
Long-acting options such as dalbavancin, oritavancin, extended-release buprenorphine and long-acting injectable antipsychotics can bridge patients who face barriers to daily oral therapy.
Last updated: October 2026
18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge
Note
Exam scope: 2025 outline subtopic 2A5 (Social Determinants of Health) with counseling and access skills from 2C9. Device counseling is covered in Section 16.3, transitions of care and culture callbacks in Section 14.2, and EMTALA in Section 18.4.
Why Social Determinants Matter in the ED
For many patients, the ED is their main point of contact with health care. An ideal prescription fails if the patient cannot afford it, cannot reach a pharmacy, cannot read the label, has nowhere to refrigerate it, or skips meals while taking a drug that lowers blood glucose. Social conditions drive return visits, readmissions and preventable deaths as much as drug choice does.
Healthy People 2030 Domains
- Domain ED examples that affect medication use
- Economic stability Cost-related nonadherence, unstable work, no paid sick leave
- Education access and quality Limited health literacy and numeracy
- Health care access and quality No insurance or primary care, prior authorization delays, pharmacy deserts
- Neighborhood and built environment Housing instability, no transportation, unsafe storage
- Social and community context Isolation, interpersonal violence, discrimination
- Screening and Current Expectations
Common tools:
The CMS Accountable Health Communities health-related social needs screening tool , with core questions on housing, food, transportation, utilities and interpersonal safety
- PRAPARE
- The two-question Hunger Vital Sign
Regulatory and accreditation status:
CMS removed the hospital measures Screening for Social Drivers of Health and Screen Positive Rate for Social Drivers of Health from the Inpatient Quality Reporting program in the FY 2026 IPPS final rule .
The Joint Commission's 2026 National Performance Goals still require hospitals to assess patients' health-related social needs and give information about community resources. Examples include transportation, difficulty paying for prescriptions , education and literacy, food insecurity and housing insecurity.
The same goal requires hospitals to stratify quality data by sociodemographic characteristics and act on at least one identified disparity.
Screening is only useful when it leads to action: a social work referral, a community health worker, a cheaper drug or a medication delivered to the bedside.
Bias and Disparities
Studies of ED analgesia have repeatedly found that Black and Hispanic patients are less likely than White patients to receive opioid analgesia for the same painful conditions. Standardized pain protocols, order sets and audits of prescribing data stratified by patient group help reduce these unwarranted differences.
Cost and Insurance Barriers
Ask directly , for example "How do you usually pay for your medicines, and is cost ever a problem?", and check prescription benefit information in the EHR when it is available.
Medicare Part D: the Inflation Reduction Act created an annual out-of-pocket cap of $2,000 in 2025, rising to $2,100 in 2026 , and the Medicare Prescription Payment Plan lets beneficiaries spread costs over the year. Covered insulin cost sharing is limited to $35 a month .
Uninsured and underinsured patients:
Prefer drugs on low-cost generic lists.
Use manufacturer patient assistance programs. Copay cards cannot be used with Medicare or Medicaid.
Use the hospital's 340B program and charity care, and charitable vouchers.
Prior authorization: for urgent drugs, choose a covered alternative or provide a bridge supply rather than send the patient home without therapy.
Practical Access Strategies at Discharge
Barrier Pharmacist strategy
Pharmacy closed or far away "Meds to Beds" bedside delivery from the outpatient pharmacy; first doses or take-home packs where state law allows
No transportation Delivery or mail order, or prescriptions sent to a pharmacy near home or work
Cannot afford a brand-name drug Therapeutic alternative from the low-cost list; samples policy; assistance program
- Complex regimen Simplify to once-daily dosing, combination products and blister packs
- Need for naloxone Take-home naloxone handed out in the ED ("leave-behind" kits); OTC 4 mg nasal spray
- Health Literacy, Numeracy and Language
National adult literacy data show that only about 12% of US adults have proficient health literacy . Many patients cannot use a dosing chart or a weight-based liquid dose correctly.
Use plain language , the teach-back method, pictograms, and oral syringes marked in milliliters only (never teaspoons).
Give written instructions in the patient's preferred language.
Language access is a legal requirement: Title VI of the Civil Rights Act and Section 1557 of the Affordable Care Act require meaningful access, including qualified interpreters. The Joint Commission's 2026 goals include providing interpreting and translation services. Do not use family members, especially children, as interpreters for medication counseling.
- Designing Regimens Around Patients' Circumstances
- Homelessness and Unstable Housing
Storage and theft: most insulin vials and pens can be kept at room temperature for about 28 days once opened (check the specific product). Smaller supplies and secure storage reduce theft of controlled substances.
Long-acting therapies that avoid daily doses:
Dalbavancin (1,500 mg IV once, or 1,000 mg then 500 mg a week later) or oritavancin (1,200 mg IV once) for skin infections when completing oral antibiotics is unlikely.
Long-acting injectable antipsychotics.
Extended-release buprenorphine injections for opioid use disorder.
Coordinate with shelters, street medicine teams and respite programs.
Food Insecurity
Insulin and sulfonylureas cause hypoglycemia when meals are skipped . Choose agents with lower hypoglycemia risk, reduce doses, and connect patients with food resources.
Substance Use Disorder
ED-initiated buprenorphine doubles engagement in treatment at 30 days compared with referral alone (D'Onofrio, JAMA 2015).
The federal X-waiver was eliminated in December 2022 , so any practitioner with a Schedule III DEA registration can prescribe buprenorphine for opioid use disorder.
DEA's 2023 rule allows practitioners to dispense up to a 3-day supply at once while arranging treatment (Section 18.4).
Pair treatment with naloxone and harm reduction: syringe services, fentanyl test strips where legal, and peer recovery coaches.
Caregivers, Disability and Cognition
Involve caregivers in teaching, provide large-print labels and adherence aids, and confirm that the person who will give the medication, not just the patient, understands the plan.